



# Health Research Authority

## East Midlands - Nottingham 2 Research Ethics Committee

Equinox House  
City Link  
Nottingham  
NG2 4LA

**Please note:** This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval

17 November 2021

Prof Nikola Sprigg  
Professor of Stroke Medicine  
University of Nottingham  
DCN Hub, D Floor, South Block  
Queen's Medical Centre, Derby Road  
Nottingham  
NG7 2UH

Dear Prof Sprigg

<b>Study title:</b>	<b>Tranexamic acid for Hyperacute Spontaneous Intracerebral Haemorrhage (TICH-3)</b>
<b>REC reference:</b>	<b>21/EM/0243</b>
<b>Protocol number:</b>	<b>21022</b>
<b>EudraCT number:</b>	<b>2021-001050-62</b>
<b>IRAS project ID:</b>	<b>297457</b>

Thank you for your letter of 11 November 2021, responding to the Research Ethics Committee's (REC) request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair and Lead reviewer.

### Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation

as revised, subject to the conditions specified below.

### **Good practice principles and responsibilities**

The [UK Policy Framework for Health and Social Care Research](#) sets out principles of good practice in the management and conduct of health and social care research. It also outlines the responsibilities of individuals and organisations, including those related to the four elements of [research transparency](#):

1. [registering research studies](#)
2. [reporting results](#)
3. [informing participants](#)
4. [sharing study data and tissue](#)

### **Conditions of the favourable opinion**

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS management permission (in Scotland) should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for research is available in the Integrated Research Application System.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations

### **Registration of Clinical Trials**

All research should be registered in a publicly accessible database and we expect all researchers, research sponsors and others to meet this fundamental best practice standard.

It is a condition of the REC favourable opinion that **all clinical trials are registered** on a publicly accessible database within six weeks of recruiting the first research participant. For this purpose, 'clinical trials' are defined as the first four project categories in IRAS project filter question 2. Failure to register a clinical trial is a breach of these approval conditions, unless a deferral has been agreed by or on behalf of the Research Ethics Committee (see here for more information on requesting a deferral):



# Health Research Authority

<https://www.hra.nhs.uk/planning-and-improving-research/research-planning/research-registration-research-project-identifiers/>

If you have not already included registration details in your IRAS application form, you should notify the REC of the registration details as soon as possible.

For CTIMPs involving both UK and EU sites a record in the [EU Clinical Trials Register](#) (other than adult Phase 1 studies) will exist and will satisfy the requirement for registration.

For CTIMPs only taking place in the UK, sponsors must register the trial on an established international registry which is a Primary Registry listed in the [WHO Registry Network](#) or the [ICMJE list](#) of registries e.g. the [ISRCTN registry](#) or [ClinicalTrials.gov](#).

You should notify *both* the REC and the [MHRA](#) of the registration details.

Further guidance on registration is available at:

<https://www.hra.nhs.uk/planning-and-improving-research/research-planning/transparency-responsibilities/>

## Publication of Your Research Summary

We will publish your research summary for the above study on the research summaries section of our website, together with your contact details, no earlier than three months from the date of this favourable opinion letter.

Should you wish to provide a substitute contact point, make a request to defer, or require further information, please visit:

<https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/>

**N.B. If your study is related to COVID-19 we will aim to publish your research summary within 3 days rather than three months.**

During this public health emergency, it is vital that everyone can promptly identify all relevant research related to COVID-19 that is taking place globally. If you haven't already done so, please register your study on a public registry as soon as possible and provide the REC with the registration detail, which will be posted alongside other information relating to your project. We are also asking sponsors not to request deferral of publication of research summary for any projects relating to COVID-19. In addition, to facilitate finding and extracting studies related to COVID-19 from public databases, please enter the WHO official acronym for the coronavirus disease (COVID-19) in the full title of your study. Approved COVID-19 studies can be found at: <https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/>

Clinical trial authorisation must be obtained from the Medicines and Healthcare products Regulatory Agency (MHRA).



# Health Research Authority

**It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).**

## **After ethical review: Reporting requirements**

The attached document "After ethical review – guidance for researchers" gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study, including early termination of the study
- Final report
- Reporting results

The latest guidance on these topics can be found at

<https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/>.

## **Ethical review of research sites**

### NHS/HSC sites

The favourable opinion applies to all NHS/HSC sites taking part in the study, subject to confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or management permission (in Scotland) being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

### Non-NHS/HSC sites

I am pleased to confirm that the favourable opinion applies to any non-NHS/HSC sites listed in the application, subject to site management permission being obtained prior to the start of the study at the site.

## **Approved documents**

The final list of documents reviewed and approved by the Committee is as follows:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Covering letter on headed paper [Cover Letter REC]		12 August 2021
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Insurance letter]		20 July 2020
Investigator's brochure / IMP Dossier [IMP label]	1.0	09 August 2021
IRAS Application Form [IRAS_Form_17092021]		17 September 2021
IRAS Application Form XML file [IRAS_Form_17092021]		17 September 2021
IRAS Checklist XML [Checklist_05102021]		05 October 2021



# Health Research Authority

Letter from funder [Funder's Letter]		30 November 2020
Letter from sponsor [Sponsor Letter Signed]		13 August 2021
Non-validated questionnaire [TICH-3_Day_180_follow-up_20211011_v1.0_posta]	1.0	11 October 2021
Other [TICH-3 Consent Process 12.10.2021 figure with tracked changes]	1.0	12 October 2021
Other [Consent Flow Chart]	1.0	09 November 2021
Other [Participant Consent Form with Track Changes ]	0.3	03 November 2021
Other [Participant Information Sheet with track changes]	0.3	03 November 2021
Other [Participant Short Information Sheet with track changes]	0.3	02 November 2021
Other [Professional Legal Representative Full Consent Form with track changes]	0.3	03 November 2021
Other [Professional Legal Representative Information Sheet with track changes]	0.4	03 November 2021
Other [Professional Legal Representative Short Information Sheet and Consent with track changes]	0.2	03 November 2021
Other [Relative Legal Representative Full Consent Form with track changes]	0.3	03 November 2021
Other [Relative Legal Representative Full Information Sheet with track changes]	0.4	03 November 2021
Other [Relative Legal Representative Short Information Sheet with track changes]	0.3	03 November 2021
Other [TICH-3 Protocol with track changes]	1.4	03 November 2021
Other [Nikki Sprigg CV]	1.0	09 November 2021
Other [Clinical Trial Authorisation Document]	1.0	03 November 2021
Other [GP Letter]	0.2	03 November 2021
Other [Day 180 Follow Up Questionnaire]	1.0	11 October 2021
Other [Clinical Trials Insurance Certificate]	1.0	26 July 2021
Other [REC Response Letter]	1.1	09 November 2021
Other [Participant Full Consent Form Clean]	1.0	03 November 2021
Other [Participant Information Sheet Clean]	1.0	03 November 2021
Other [Participant Short Information Sheet Clean]	1.0	03 November 2021
Other [Professional Legal Representative Full Consent Form Clean]	1.0	03 November 2021
Other [Professional Legal Representative Information Sheet Clean]	1.0	03 November 2021
Other [Professional Legal Representative Short Information Sheet and Consent Form Clean]	1.0	03 November 2021
Other [Relative Legal Representative Full Consent Form Clean]	1.0	03 November 2021
Other [Relative Legal Representative Information Sheet Clean]	1.0	03 November 2021
Other [Relative Legal Representative Short Information Sheet Clean]	1.0	03 November 2021
Other [TICH-3 Protocol]	1.0	03 November 2021
Summary CV for Chief Investigator (CI) [Philip Bath's CV]		30 March 2020



# Health Research Authority

Summary of product characteristics (SmPC) [SmPC TXA]	11 April 2019
--	---------------

## Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

## User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website:

<http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/>

## HRA Learning


We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at:

<https://www.hra.nhs.uk/planning-and-improving-research/learning/>

<b>IRAS project ID: 297457     Please quote this number on all correspondence</b>
---

With the Committee's best wishes for the success of this project.

Yours sincerely

PP 

**Ms Bernadette Roberts**  
**Chair**

Email: [nottingham2.rec@hra.nhs.uk](mailto:nottingham2.rec@hra.nhs.uk)

*Enclosures:* "After ethical review – guidance for researchers" [\[SL-AR1\]](#)

*Copy to:* Ms Angela Shone

*Lead Nation England:* [approvals@hra.nhs.uk](mailto:approvals@hra.nhs.uk)